• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Leflunomide Induced Atypical DRESS: A Case Report and Literature Review
We report a case of a lady aged 32 years, presented to our hospital with a history of leflunomide intake and symptoms of DRESS.PMID:37223589 | PMC:PMC10201105 | DOI:10.31138/mjr.34.1.91
Source: Herpes - May 24, 2023 Category: Infectious Diseases Authors: Maryam Fatima Salwa Sahar Azimi Soumya Ashwini Madhuri H Radhakrishna Source Type: research

Severe Cutaneous Adverse Reaction Caused by Carbamazepine and Levofloxacin After Varicella Zoster Virus Infection
Infect Drug Resist. 2023 Mar 23;16:1705-1711. doi: 10.2147/IDR.S402267. eCollection 2023.ABSTRACTSevere cutaneous adverse reactions (SCARs) to drugs are associated with morbidity, mortality, healthcare costs, and challenges in drug development. It is important to identify the SCAR type early by using strict diagnostic criteria because they may require different treatments, follow-ups, and short- or long-term prognoses. A 68-year-old woman admitted to our hospital presented with fever and rashes for 10 days. This case exhibited many features that suggested acute generalized exanthematous pustulosis (AGEP). However, the cour...
Source: Herpes - April 6, 2023 Category: Infectious Diseases Authors: Meifang Wang Li Lin Leyi Wang Linfeng Li Source Type: research

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Using the Self-Controlled Tree-Temporal Scan Statistic to Assess the Safety of Live Attenuated Herpes Zoster Vaccine.
Abstract The self-controlled tree-temporal scan statistic allows detection of potential vaccine- or drug-associated adverse events without pre-specifying the specific events or post-exposure risk intervals of concern. It thus opens a promising new avenue for safety studies. The method has been successfully used to evaluate the safety of two vaccines for adolescents and young adults, but its suitability to study vaccines for older adults had not been established. The current study applied the method to assess the safety of live attenuated herpes zoster vaccination during 2011-2017 in U.S. adults ≥ 60 years old, u...
Source: Am J Epidemiol - May 6, 2019 Category: Epidemiology Authors: Yih WK, Kulldorff M, Dashevsky I, Maro JC Tags: Am J Epidemiol Source Type: research

Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
This study was carried out in accordance with the recommendations of The London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics Committee (Ref. 6123) and the National Research Ethics Service (NRES) London-Bloomsbury Research Ethics Committee (REC ref. 11/10/1760, IRAS ID: 77765), with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the LSHTM Research Ethics Committee and the NRES London-Bloomsbury Research Ethics Committee. Author Contributions JC, HD, LN, EL, and ER devised the study ...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Psoriasis and herpes are most stigmatized dermatologic conditions
Attitudes toward psoriasis and herpes are significantly more stigmatizing than are perceptions of other dermatologic conditions, reported Dr. Jessica M. Donigan and her associates from Massachusetts General Hospital in...
Source: Skin and Allergy News - September 9, 2015 Category: Dermatology Source Type: news

“I’m Just In the Band”
Discussion Instrumental music, either as an avocation or profession, provides great pleasure for those performing and listening. Unfortunately it can also cause health problems. Many of the problems are musculoskeletal or neurological in etiology due to overuse and the musician may experience pain. Prelude to pain can include stiffness or tingling or other skin sensations. Musicians may experience weakness, loss of function, control (accuracy) and ability (speed) as well as problems with tone. “The most prevent problems involve overuse of muscles resulting from repetitive movements of playing, often in combination w...
Source: PediatricEducation.org - November 17, 2014 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news